National Health Surveillance Agency Temporarily Suspends Two Medications, Including an Antibiotic and an Anesthetic, After Report of Contamination and Color Change in Batches Manufactured in Brazil
The ANVISA determined the preventive ban of two medications produced in the country after identifying possible quality failures in specific batches. One of the cases involves the finding of an insect inside a vial of anesthetic, which led to the immediate suspension of the distribution and use of the product.
The measure, published in the Official Gazette of the Union, affects the antibiotic Vancotrate 500 mg, from União Química, and lidocaine hydrochloride 20 mg/mL, from Hipofarma. According to ANVISA, the ban is temporary and precautionary, adopted to protect the population until laboratory analyses on the affected batches are completed.
Banned Batches and Risks Assessed by ANVISA
The most serious case involves the anesthetic lidocaine hydrochloride, used in hospital and dental procedures, in which an insect was found inside a sealed vial.
-
China launches a destination-less cruise with a giant domestically-made ship, departing from Shanghai for 3 days without stops, turning the ship itself into an attraction, offering a new way to travel without rushing between ports along the Chinese coast.
-
Dissatisfied with families sleeping on the streets of São Paulo, the city hall created villages with modular houses of 18 m², bathroom, sink, beds, refrigerator, stove, laundry, garden, and even parking for carts to help people rebuild their lives away from the crowded shelters.
-
Young people from Ghana transform urban waste into a “zero waste” model, reduce air pollution by up to 70%, win a global prize of £1 million, and aim to spread the solution across Africa.
-
China develops a snake-inspired system that sees heat in 4K at room temperature using common CMOS sensors and could bring infrared vision to cameras and cell phones.
The affected batch is valid until January 2027, and all of its commercialization and use have been immediately suspended.
In the case of the antibiotic Vancotrate 500 mg, the ban applies to a batch with validity until April 2027, which showed color change after dilution, a behavior different from that specified in the medication’s package insert.
Physical alterations are indicative of possible instability or contamination, which led the agency to determine the preventive blocking of the product throughout the national territory.
Reactions from Manufacturers and Ongoing Investigations
União Química, manufacturer of Vancotrate, reported that it is investigating the causes of the color change and that it fully complies with all ANVISA determinations.
The company emphasized that the problem was identified in only one batch and that other units remain under analysis to ensure safety and stability.
Meanwhile, Hipofarma, responsible for the anesthetic, stated that it found no signs of contamination in its internal processes and reported that the very client who made the complaint later retracted.
Nonetheless, ANVISA maintained the ban as a precaution, following the sanitary safety protocol until the conclusion of official analyses.
Safety Procedures and Guidance for Healthcare Professionals
During the ban period, the medications cannot be used, sold, or distributed.
ANVISA advises that healthcare professionals immediately suspend the use of the products and report any suspicion of adverse events to the National Health Surveillance System.
The ban does not imply definitive withdrawal, but serves to prevent potentially contaminated medications from reaching patients before the completion of quality control tests.
The preventive decision is one of the most stringent sanitary protection tools used by the agency to avoid risks to public health.
Preventive Measures and Impact on the Pharmaceutical Market
Cases of preventive bans on medications reinforce the importance of traceability mechanisms, quality control, and quick response from regulatory agencies.
Situations like this often lead to immediate adjustments in the production chain and revision of safety protocols in the involved pharmaceutical industries.
In addition to consumer protection, these actions serve as a warning to manufacturers, distributors, and healthcare professionals about the need to verify the physical integrity of medications before use.
The occurrence of foreign bodies or visual alterations, even if isolated, should be reported to the authorities for formal investigation.

-
1 person reacted to this.